Skip to main content
. 2020 Feb 1;93(1106):20180781. doi: 10.1259/bjr.20180781

Table 2.

Variables measured before and during treatment and impact on OS, DFS and LC, (p < 0.05*); Spearman Rank Correlation with time to event or censoring

Variable No. of patients Median/range pOS R
Spearman		 OS Above/below median (mts) pLC R
Spearman		 LC
Above/below median
(mts)		 pDFS R
Spearman		 DFS Above/below median
(mts)
VCT 33 26.5 (0.2–174.3) 0.05 −0.316 15.5/39 0.01a −0.407 10/35 0.007a −0.461 9.5/25
VCT1 14 Gy 26 18.8 (0–74.8) 0.13 −0.301 14/32 0.04a −0.413 8/24 0.13 −0.323 8/25
VCT2 28 Gy 24 12.6 (0–68.9) 0.03a −0.44 13/36 0.03a −0.463 6.5/31 0.007a −0.611 6.5/31.5
VCT3 36 Gy 20 7.4 (0–55.7) 0.03a −0.504 13/21 0.04a −0.464 8.5/18 0.02a −0.609 8.5/18
V[18F]LT 33 16.8 (0.9–66.6) 0.17 −0.225 15/35 0.03a −0.277 8/24 0.04a −0.374 8/24
V[18F]LT 14 Gy 24 6.4 (0–47.9) 0.59 −0.113 16/43 0.32 −0.222 10/34 0.2 −0.290 10.5/34
V[18F]LT 28 Gy 22 0.3 (0–19.6) 0.4 −0.184 14.5/17 0.16 −0.320 10/13 0.22 −0.303 9.5/14
V[18F]DG 33 18.7 (0.5–108) 0.24 −0.192 17/36 0.04a −0.336 13/24 0.05 −0.340 11/13
V[18F]MISO 1.5 33 1.2 (0.1–18.5) 0.83 −0.037 19/NA 0.38 −0.160 15/NA 0.33 −0.191 14/NA
V[18F]MISO 1.5 36 Gy 20 0 (0–3.4) 0.08 −0.404 17/NA 0.07 −0.416 13/NA 0.16 −0.364 14/NA
V[18F]MISO 1.6 33 0.85 (0.1–14.4) 0.76 −0.053 17/NA 0.23 −0.214 13/NA 0.14 −0.278 14/NA
V [18F]MISO 1.6 36 Gy 20 0 (0–1.6) 0.28 −0.258 17/NA 0.37 −0.215 13/NA 0.16 −0.364 14/NA
[18F]MISO SUVmax 33 1.7 (1.5–2.5) 0.66 −0.074 17/27 0.24 −0.207 13/24 0.06 −0.347 13/24
[18F]MISO SUVmax 36 Gy 4/20a 1.5 (0.7–1.8) 0.69 −0.097 19/14 0.51 −0.158 15.5/12 0.64 −0.125 14/13
[18F]LT SUVmax 33 6.5 (2.6–16) 0.2 −0.210 14.5/37.5 0.1 −0.277 10–29.5 0.2 −0.231 7.5/2.5
[18F]LT SUVmax 14 Gy 21 3 (0.5–6.4) 0.25 −0.257 0.24 −0.282 9/31 0.09 −0.405 9/32
[18F]LT SUV max 28 Gy 11/20a 3.2 (1.9–4.5) 0.85 −0.059 17/34
14/15		 0.9 −0.038 2/12 0.51 0.250 3/11
[18F]DG SUVmax 33 11.3 (2.9–18.3) 0.85 −0.033 17/21 0.45 −0.136 13/21 0.23 −0.229 8.5/13
TMRmax 33 1.4 (0.9–2.9) 0.065 −0.315 16.5/27 0.03a −0.364 13/20 0.04a −0.375 13.5/21
TMRmax 36 Gy 20 1.2 (0.9–2.7) 0.38 −0.214 19/16 0.38 −0.214 16.6/13 0.58 −0.147 12.5/14
[18F]DG MTV 33 23.2 (2.4–106.7) 0.11 −0.263 15.5/36 0.005a −0.446 6.5/24 0.04a −0.355 6.5/14
[18F]LT MTV 33 20.1 (0.9–135.5) 0.15 −0.237 16/36 0.02a −0.392 12/24 0.05a −0360 9/24
[18F]MISO MTV 33 0 (0–14.9) 0.81 −0.042 17/NA 0.32 −0.181 13/NA 0.25 −0.224 14/NA

[18F]-FDG, [18F]-2-flu-2-deoxy-D-glucose; [18F]-FLT, [18F]-flu-3'deoxythymidine; [18F]-FMISO, [18F]-flumisonidazole; LC, local control; OS, overall survival; SUVmax, maximum standardised uptake value; VCT, CT tumour volume.

V – baseline tumour volume in CT, FDG, FLT, FMISO.

V14Gy, 28 Gy, 36 Gy – tumour volume measured at indicated time point during treatment.

VFMISO 1.5, 1.6 – hypoxic tumour volume based on indicated threshold levels.

MTV FDG, FLT, FMISO – metabolic tumour volume.

SUVmax– baseline maximum standardised uptake value.

TMRmax – baseline Tumour-Muscle-Ratio based on SUVmax.

TMRmax 36 Gy – Tumour-Muscle-Ratio based on SUVmax at 36 Gy.

OS, LC, DSF above/below median – time of survival or control for values of variables above or below median.

a

number of patients with residual uptake of tracer at selected time point/all patients analysed in selected time point